NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · MID CAP
Myriad Genetics Inc. MYGN
18 fiscal years on record · USD · FY2025 reported · SEC filings only
$-365.9M
In brief
What this company does
Written from the business description in MYRIAD GENETICS INC's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.
Growth
USD 824.5M
Revenue, FY2025 · full 18-year series below
Revenue $M
Net income $M
FY2025 · Revenue 824.5 · Net income -365.9
Compound annual growth
Revenue compounded at +8.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−44 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -47.0% · Net -44.4%
ROE
FY2025 · ROE -68.5%
Each USD of equity lost 68 cents this year.
The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.9 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 |
| Operating income $B | −0.4 | −0.1 | −0.3 | −0.1 | −0.2 | −0.3 | −0.2 | 0.0 | 0.1 | 0.0 | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
| EBITDA $B | −0.4 | −0.1 | −0.2 | −0.1 | −0.2 | · | −0.2 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
| Income tax $B | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | −0.0 | 0.0 |
| Net income $B | −0.4 | −0.1 | −0.3 | −0.1 | −0.0 | −0.2 | −0.2 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
| Free cash flow $B | · | · | · | −0.2 | 0.0 | · | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| EPS, diluted $ | −3.95 | −1.41 | −3.18 | −1.39 | −0.35 | −2.99 | −2.69 | 0.06 | 1.85 | 0.25 | 1.60 | 1.07 | 2.25 | 1.77 | 1.30 | 1.10 | 1.54 | 0.86 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −68.5 | −17.2 | −31.6 | −12.1 | −2.9 | −24.9 | −19.9 | 0.4 | 15.4 | 2.3 | 16.7 | 11.6 | 24.3 | 21.6 | 18.7 | 17.9 | 30.7 | 19.7 |
| Shares out B | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Myriad Genetics Inc.vsIdexx Laboratories Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsQuidelOrtho Corp.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsLantheus Holdings, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsNeogen Corp.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsIntellia Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsCelldex Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsTrinity Biotech PLCSame industry: In Vitro & In Vivo Diagnostic Substances
Provenance
Company facts, as filed
How we verify · 0 failures in 75 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 11 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007